How is genital warts best treated?

Genital warts—clinically known as condylomata acuminata—are caused by certain low-risk strains of human papillomavirus (HPV), most commonly HPV types 6 and 11. Treatment is aimed at removing visible lesions, alleviating symptoms such as itching or discomfort, and reducing transmission risk—but it does not eradicate latent HPV infection. Therefore, recurrence is common, and management requires both lesion-directed therapy and patient-centered counseling.

First-line treatment options depend on lesion size, location, number, and patient preference. For small, external lesions, topical therapies are often preferred: imiquimod 3.75% or 5% cream (applied three times weekly for up to 16 weeks) stimulates local immune response; podofilox 0.5% solution or gel (applied twice daily for three days, followed by four days off—repeated for up to four cycles); or sinecatechins 15% ointment (applied three times daily for up to 16 weeks). These agents are self-administered and avoid procedural discomfort, though they require strict adherence and may cause local inflammation.

For larger, resistant, or periurethral/anal warts, provider-administered modalities are more effective. Cryotherapy with liquid nitrogen (applied every 1–2 weeks) remains widely used due to its safety and accessibility. Electrocautery, surgical excision, or CO₂ laser ablation offer rapid clearance for extensive or recurrent disease but carry higher risks of scarring, pain, and need for anesthesia. Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80–90% can be applied cautiously to small, dry lesions—though it requires expertise to avoid chemical burns.

It’s essential to emphasize that no treatment eliminates HPV DNA from infected keratinocytes. Patients should be counseled on the natural history of infection: many cases resolve spontaneously within 12–24 months, especially in immunocompetent individuals. However, persistent infection warrants evaluation for immunosuppression (e.g., HIV) or high-risk HPV co-infection. Vaccination with the 9-valent HPV vaccine is strongly recommended—even after diagnosis—as it protects against additional oncogenic and wart-causing types and may reduce recurrence risk.

Finally, sexual partners should be evaluated clinically; routine HPV testing is not indicated, but screening for other STIs is advised. Consistent condom use decreases—but does not eliminate—transmission risk. Follow-up every 3 months during active treatment and for at least 6 months post-clearance helps detect early recurrence and supports long-term management.